Press Release Thursday 28th June 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Share Placing completed to Miton Asset Management
Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that the share Placing of 12,500,000 new Ordinary Shares at a subscription price of 4 pence per share announced on Wednesday 27 June, raising £500,000 before expenses, has been successfully completed with LF Miton UK Smaller Companies Fund.
Following admission of the Placing shares, the Company’s enlarged issued share capital will comprise 436,900,000 Ordinary Shares.
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private. Sativa Investments’ first two deals include Canadian-based, tri-listed, emerging global pharmaceutical company,Veritas Pharma Inc., and Toronto-based Pharma-Tech company that owns the patent-pending proprietary QuickStrip™ technology, Rapid Dose Therapeutics Inc.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: https://sativainvestments.com/